Description

Fmoc-Gly3-VC-PAB-MMAE is a Drug-Linker Conjugates for ADC. Fmoc-Gly3-VC-PAB-MMAE consists of Monomethyl auristatin E (HY-15162) and a linker[1].–Applications-Cancer-programmed cell death-Formula-C79H113N13O17-Citation–References-[1]Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.-CASNumber–MolecularWeight-1516.82-Compound Purity–SMILES-CC[C@@H]([C@H](N(C)C([C@@H](NC([C@@H](N(C)C(OCC1=CC=C(C=C1)NC([C@@H](NC([C@@H](NC(CNC(CNC(CNC(OCC2C3=C(C=CC=C3)C4=C2C=CC=C4)=O)=O)=O)=O)C(C)C)=O)CCCNC(N)=O)=O)=O)C(C)C)=O)C(C)C)=O)[C@H](OC)CC(N5[C@H]([C@H](OC)[C@H](C(N[C@@H]([C@H](C6=CC=CC=C6)O)C)=O)C)CCC5)=O)C-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Drug-Linker Conjugates for ADC-Isoform–Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related